Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne®CDx compared with amplicon-based OncomineDX
In summary, in advanced NSCLC, hybrid capture-based NGS, such as F1CDx, may capture more actionable genomic alterations as compared with ODxTT, an amplicon-based NGS.
Authors
- Richard S.P. Huang (ORCID: https://orcid.org/0000-0001-8395-5168)
- Vidyalakshmi Sethunath (ORCID: https://orcid.org/0000-0002-3308-3063)
- Brennan Decker
- Amaya Gascó
- Jeffrey S. Ross (ORCID: https://orcid.org/0000-0001-5865-6828)
- Andreas M. Heilmann (ORCID: https://orcid.org/0000-0003-3906-8830)
- Katherine T Lofgren (ORCID: https://orcid.org/0000-0002-3346-5504)
- Kuei‐Ting Chen
- Ericka Ebot
- Sarah Smith
Institutions
- SUNY Upstate Medical University (US)
- Boston Foundation (US)
- Foundation Medicine (United States)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1093/oncolo/oyaf390
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Foundation Medicine